Alzamend Neuro, Inc.
Close on Oct 19, 2026
- Market cap
- $5.96M
- P/E (TTM)
- –
- Dividend yield
- –
About Alzamend Neuro
Pharmaceutical Preparations, SIC 2834
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological and psychiatric conditions, including Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company’s pipeline consists of two therapeutic drug candidates: AL001 and ALZN002. AL001 is a patented ionic cocrystal combining lithium, salicylate, and proline, designed to address neurodegenerative and mood disorders while potentially improving lithium's safety and pharmacokinetic profile. ALZN002 is a cell-based therapeutic vaccine utilizing a mutant peptide sensitized cell to stimulate an immunological response against Alzheimer’s disease.
The company operates in the United States and has principal executive offices located in Atlanta, Georgia. Its drug candidates remain in clinical and preclinical evaluation and have not received commercial regulatory approval. Alzamend seeks to advance its product pipeline through regulatory development pathways, intending to partner with established pharmaceutical companies for manufacturing and commercial distribution rather than marketing therapies directly.
Summary of the business section of Alzamend Neuro's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alzamend Neuro, Inc.
- Headquarters
- Atlanta, GA
- Address
- 480 Peachtree Road Ne, Second Floor, Suite 103 30326
- Phone
- (844) 722-6333
- Website
- alzamend.com
- Employees
- 4, Apr 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- April 30
- Auditor
- HASKELL & WHITE LLP, Irvine, California
Stock & identifiers
- Ticker
- ALZN
- Exchange
- Nasdaq
- IPO date
- Jun 15, 2021
- Shares outstanding
- 5M, Sep 10, 2026
- Public float
- $9.60M, Oct 31, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-9 reverse, Jul 22, 2025; 1-for-9 reverse, May 12, 2025; 1-for-10 reverse, Jul 30, 2024; 1-for-10 reverse, Jul 16, 2024; 1-for-15 reverse, Dec 15, 2023; 1-for-15 reverse, Oct 31, 2023
- SEC CIK
- 1677077
- CUSIP
- 02262M605
- ISIN
- US02262M6057
- LEI
- 549300W6G6EUO4ZRIB82
- EIN
- 81-1822909
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Henry Carl Nisser | EVP and General Counsel, Director | – |
| Stephan Jackman | Chief Executive Officer, Director | 45,500 |
| David J. Katzoff | Chief Financial Officer | 5,540 |
| Milton C. Ault Iii | Director | 129,777 |
| Ault Capital Group, Inc. | Director | – |
| Ault Lending, LLC | Director | – |
| Hyperscale Data, Inc. | Director | – |
| William B. Horne | Director | 0 |
| Jeffrey Oram | Director | 100,000 |
| Mark Gustafson | Director | 60,000 |
| Lynne Fahey McGrath | Director | 25 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $468.29K | $467.25K | $150.00K | $0 | $0 |
| FY2025 Non Peo Neo | $150.00K | $150.00K | $150.00K | $0 | $0 |
| FY2025 Peo | $468.29K | $467.25K | $150.00K | $0 | $0 |
| FY2024 | $443.62K | $106.29K | $150.00K | $0 | $1 |
| FY2024 Non Peo Neo | $150.00K | $150.00K | $150.00K | $0 | $1 |
| FY2024 Peo | $443.62K | $106.29K | $150.00K | $0 | $1 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of April 30, 2026, we had four full-time employees and two part-time employees.”
Corporate history
Events identified from SEC filings